Displaying drugs 7226 - 7250 of 8297 in total
Crefmirlimab
Crefmirlimab is an anti-human CD8 probe targeting the CD8 antigen, for the diagnosis of various cancers.
Investigational
Matched Description: … Crefmirlimab is an anti-human CD8 probe targeting the CD8 antigen, for the diagnosis of various cancers …
MEDI-491
MEDI-491 is a recombinant human parvovirus B19 vaccine composed of the VP1 and VP2 capsid proteins.
Investigational
Matched Description: … MEDI-491 is a recombinant human parvovirus B19 vaccine composed of the VP1 and VP2 capsid proteins. …
BHT-3034
BHT-3034 is a DNA plasmid vaccine immunotherapy under investigation for the treatment of myasthenia gravis.
Investigational
Matched Description: … BHT-3034 is a DNA plasmid vaccine immunotherapy under investigation for the treatment of myasthenia gravis …
ST-003
ST-003 is a novel galanin receptor inhibitor being investigated for the treatment of primary sclerosing cholangitis.
Investigational
Matched Description: … ST-003 is a novel galanin receptor inhibitor being investigated for the treatment of primary sclerosing …
RAG-17
RAG-17 is a siRNA oligonucleotide designed to target and knockdown the expression of superoxide dismutase (SOD).
Investigational
Matched Description: … RAG-17 is a siRNA oligonucleotide designed to target and knockdown the expression of superoxide dismutase …
PARPI F-18
PARPI F-18 is a diagnostic agent under investigation for use in the management of glioblastoma multiforme.
Investigational
Matched Description: … PARPI F-18 is a diagnostic agent under investigation for use in the management of glioblastoma multiforme …
Peresolimab
Peresolimab is under investigation in clinical trial NCT04634253 (A Study of LY3462817 in Participants With Rheumatoid Arthritis).
Investigational
Matched Description: … Peresolimab is under investigation in clinical trial NCT04634253 (A Study of LY3462817 in Participants …
Camonsertib
Camonsertib is under investigation in clinical trial NCT04497116 (Study of RP-3500, Camonsertib, in Advanced Solid Tumors).
Investigational
Matched Description: … Camonsertib is under investigation in clinical trial NCT04497116 (Study of RP-3500, Camonsertib, in Advanced …
Ivonescimab
Ivonescimab is under investigation in clinical trial NCT05184712 (Phase 3 Clinical Study of AK112 for NSCLC Patients).
Investigational
Matched Description: … Ivonescimab is under investigation in clinical trial NCT05184712 (Phase 3 Clinical Study of AK112 for …
Ponsegromab
Ponsegromab is under investigation in clinical trial NCT05492500 (A Study of Ponsegromab in People With Heart Failure).
Investigational
Matched Description: … Ponsegromab is under investigation in clinical trial NCT05492500 (A Study of Ponsegromab in People With …
Aminoflavone
Aminoflavone is under investigation in clinical trial NCT01015521 (Efficacy Study of Aminoflavone Prodrug to Treat Breast Cancer).
Investigational
Matched Description: … Aminoflavone is under investigation in clinical trial NCT01015521 (Efficacy Study of Aminoflavone Prodrug …
Nitroxoline
Nitroxoline is a urinary antibacterial agent active against susceptible gram-positive and gram-negative organisms commonly found in urinary tract infections. It is a hydroxyquinoline derivative unrelated to other classes of drugs. Nitroxoline is active against bacterial gyrases.
Experimental
Matched Description: … It is a hydroxyquinoline derivative unrelated to other classes of drugs. …
Daledalin
Daledin (UK-3557-15) is a selective norepinephrine reuptake inhibitor. It has no effects on the reuptake of serotonin or dopamine, and no antihistamine or anticholinergic properties. It was in trials for depression in the 1970s but never marketed.
Experimental
Matched Description: … It has no effects on the reuptake of serotonin or dopamine, and no antihistamine or anticholinergic properties …
Magnesium aspartate
Magnesium aspartate is a magnesium salt of aspartic acid that is commonly used as a mineral supplement. It displays high oral bioavailability and water solubiltiy compared to other magnesium salts such as magnesium citrate, magnesium carbonate and magnesium oxide.
Experimental
Matched Description: … Magnesium aspartate is a magnesium salt of aspartic acid that is commonly used as a mineral supplement …
Talacotuzumab
Talacotuzumab is an IgG1 monoclonal antibody directed toward the IL3 receptor α–subunit, also known as CD123. It is under investigation in clinical trial NCT01632852 (A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission).
Investigational
Matched Description: … It is under investigation in clinical trial NCT01632852 (A Study of CSL362 in Patients With CD123+ Acute …
Sovleplenib
Sovleplenib is a novel, investigational, selective small molecule inhibitor for oral administration targeting spleen tyrosine kinase (Syk). It is under investigation in clinical trial NCT03483948 (Phase I Study of Hmpl-523+azacitidine in Elderly Patients With Acute Myeloid Leukemia).
Investigational
Matched Description: … It is under investigation in clinical trial NCT03483948 (Phase I Study of Hmpl-523+azacitidine in Elderly …
SRP-9005
SRP-9005 is a rAAVrh74 vector containing a codon-optimized human SGCG transgene. Developed by the Kurt+Peter Foundation and Sarepta Therapeutics, it is being investigated for the treatment of Limb-girdle muscular dystrophy (LGMD) type 2C/R5.
Investigational
Matched Description: … Developed by the Kurt+Peter Foundation and Sarepta Therapeutics, it is being investigated for the treatment of …
Piclamilast
Piclamilast (RP-73,401), is a selective PDE4 inhibitor comparable to other PDE4 inhibitors for its anti-inflammatory effects. It has been investigated for its applications to the treatment of conditions such as chronic obstructive pulmonary disease, bronchopulmonary dysplasia and asthma. The structure for piclamilast was first elucidated in a 1995 European patent...
Experimental
Matched Description: … It has been investigated for its applications to the treatment of conditions such as chronic obstructive ... first elucidated in a 1995 European patent application and exhibits the structural functionalities of …
Rindopepimut
Rindopepimut (CDX-110) is an injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases. The vaccine consists of the EGFRv3-specific peptide (a 13-amino acid mutant vIII epitope) conjugated to the non-specific immunomodulator keyhole limpet hemocyanin (KLH). The US FDA granted...
Investigational
Matched Description: … The vaccine consists of the EGFRv3-specific peptide (a 13-amino acid mutant vIII epitope) conjugated ... injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of …
Velafermin
Velafermin was a novel investigational protein therapeutic, also known as fibroblast growth factor-20 (FGF-20), which promotes both epithelial and mesenchymal cell proliferation in vitro and has demonstrated activity in multiple animal models. Velafermin was investigated as a potential therapy for the prevention and treatment of oral mucositis by fostering the...
Investigational
Matched Description: … by fostering the regeneration and repair of the cells lining the gastrointestinal tract. ... Velafermin was investigated as a potential therapy for the prevention and treatment of oral mucositis …
Valopicitabine
The 3-O-valine ester prodrug of the nucleoside analog 2'-C-methylcytidine with anti-hepatitis C virus (HCV) activity. Upon administration, valopicitabine is converted into 2'-C-methylcytidine; upon phosphorylation into its 5-triphosphate form, this metabolite inhibits viral RNA chain elongation and viral RNA-dependent RNA polymerase activity. This blocks viral production of HCV RNA and thus...
Experimental
Matched Description: … This blocks viral production of HCV RNA and thus viral replication. [from NCI] ... The 3-O-valine ester prodrug of the nucleoside analog 2'-C-methylcytidine with anti-hepatitis C virus …
Erythroxylum catuaba bark
"Catuaba" is a general term for a medicinal infusion created by the bark of plants belonging to the Erythroxylum genus, though this name is also applied to infusions of plants belonging to other genera. The infusion is thought to carry stimulant and aphrodisiac effects, and catuaba made specifically with Trichilia...
Experimental
Matched Description: … "Catuaba" is a general term for a medicinal infusion created by the bark of plants belonging to the _ ... Erythroxylum_ genus, though this name is also applied to infusions of plants belonging to other genera …
CVnCoV Vaccine
The CVnCov Vaccine (or CV07050101) is in development by CureVac AG. The vaccine uses mRNA technology to create a protein associated with SARS-CoV2, and upon administration and replication, to initiate subsequent immune responses in the body. As of June 2020, the company received regulatory approval from German and Belgian Authorities...
Investigational
Matched Description: … Phase 1 clinical trials of this vaccine (NCT04449276). ... As of June 2020, the company received regulatory approval from German and Belgian Authorities to commence …
XL999
XL999 has the potential to provide benefit to patients with lung cancer and acute myelogenous leukemia. XL999 is a new chemical entity that inhibits a spectrum of receptor tyrosine kinases (RTKs) with growth promoting and angiogenic properties, including FGFR 1/3, PDGFRα/β, VEGFR2/KDR, KIT, and FLT3. XL999 also inhibits FLT4 and...
Investigational
Matched Description: … XL999 is a new chemical entity that inhibits a spectrum of receptor tyrosine kinases (RTKs) with growth ... growth — both directly by a novel effect on tumor cell proliferation and indirectly through inhibition of …
NUC B1000
NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct designed to produce four short interfering RNA (siRNA) molecules, formulated with a proprietary cationic-lipid delivery system. eiRNA is an approach to RNAi therapeutics, whereby a plasmid DNA coding for desired dsRNA is delivered to...
Investigational
Matched Description: … NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct ... On January 11, 2008, it was announced that NUC B1000 was entering a phase 1 human safety study of its …
Displaying drugs 7226 - 7250 of 8297 in total